Immune Checkpoint Inhibitors

Explore clinical trials studying Immune Checkpoint Inhibitors. Study availability and eligibility vary by location and protocol.

27 public trials 11 recruiting studies

Refine in advanced search Browse all conditions

Immune Checkpoint Inhibitors trial results

Completed

Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology

NCT03948724

Conditions: Adenocarcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma, +29 more
Locations: Chu Angers Angers, France

Institut de Cancerologie de L'Ouest Angers, France

Centre Francois Baclesse Caen, France

Centre D'Oncologie Et de Radiotherapie 37 Chambray-lès-Tours, France

View Trial Details

Completed

Fecal Microbiota Transplantation in Patients With Malignancies Not Responding to Cancer Immunotherapy

NCT05273255

Conditions: Cancer, Fecal Microbiota Transplantation, Immune Checkpoint Inhibitors, +2 more
Locations: University of Zurich, University Hospital Zurich Zurich, Switzerland

View Trial Details

Active, Not Recruiting

COVICI-SURV: COVID-19 Vaccination Around ICI Start and Survival

NCT07729241

Conditions: COVID-19, COVID-19 Vaccination, Cancer, +14 more
Locations: Hôpital Pitié Salpêtrière / CIC-2503, Paris Paris, France

View Trial Details

Active, Not Recruiting

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

NCT05863052

Conditions: Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +46 more
Locations: Arizona Cancer Center at the Unvieristy of Arizona Tucson, Arizona, United States

University of New Mexico Comprehensive Cancer Center Albuquerque, New Mexico, United States

Stephenson Cancer Center Oklahoma City, Oklahoma, United States

Monument Health Cancer Care Institute Rapid City, South Dakota, United States

View Trial Details

Active, Not Recruiting

Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer

NCT06124378

Conditions: Colonic Diseases, Colonic Neoplasms, Colorectal Neoplasms, +10 more
Locations: The First Affiliated Hospital of Guangxi Medical University Nanning, Guangxi, China

View Trial Details

Active, Not Recruiting

HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC

NCT06632106

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +12 more
Locations: The first hospital of China medical university Shenyang, Liaoning, China

View Trial Details

Active, Not Recruiting

Relationship Between Immunity and Metabolism in Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer. ( RIMEC )

NCT04808817

Conditions: Cancer, Immune Checkpoint Inhibitors, Metabolic Diseases, +3 more
Locations: Hôpital Cochin Paris, Île-de-France Region, France

AP-HP - Hôpital Européen Georges-Pompidou Paris Paris, Île-de-France Region, France

View Trial Details

Immune Checkpoint Inhibitors

Immune Checkpoint Inhibitors trial results

Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology

Fecal Microbiota Transplantation in Patients With Malignancies Not Responding to Cancer Immunotherapy

COVICI-SURV: COVID-19 Vaccination Around ICI Start and Survival

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer

HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC

Relationship Between Immunity and Metabolism in Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer. ( RIMEC )

Related conditions